Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 9:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 853 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: End-stage Disease Clear all
Terminated Phase 2 Interventional Results available

Application of Impedance Threshold Device Technologies to Treat and Prevent Hypotension During Dialysis

NCT00576524
View directory record Official record
Conditions
Intradialytic Hypotension, End Stage Renal Disease, Low Blood Pressure
Interventions
ITD, Sham
Device
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
8 Years to 18 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 26, 2013 · Synced Oct 24, 2026, 9:59 AM EDT
Completed Phase 2 Interventional Results available

Study of the Effect of Intradialytic Vasopressin on Chronic Hypertension in Patients With End Stage Renal Disease

NCT01247090
View directory record Official record
Conditions
Hypertension, End Stage Renal Disease
Interventions
Vasopressin - Very Low Dose, Vasopressin - Low Dose, Placebo Comparator
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 24, 2026, 9:59 AM EDT
Not listed Phase 3 Interventional

VentrAssistTM LVAD for the Treatment of Advanced Heart Failure - Destination Therapy

NCT00490321
View directory record Official record
Conditions
End-stage Heart Failure, Cardiomyopathies
Interventions
VentrAssistTM Left Ventricular Assist Device
Device
Lead sponsor
Ventracor
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
27
States / cities
Birmingham, Alabama • Phoenix, Arizona • Gainesville, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2009 · Synced Oct 24, 2026, 9:59 AM EDT
Active, not recruiting Phase 2 Interventional

Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study

NCT04978584
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
Acalabrutinib, Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Prednisone, Rituximab, Tafasitamab, Vincristine
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 24, 2026, 9:59 AM EDT
Completed Not applicable Interventional

First Evaluation of the Moda-Flx Hemodialysis System™ in Real World Clinical Settings

NCT06581393
View directory record Official record
Conditions
End Stage Renal Disease, End Stage Renal Disease on Dialysis, End Stage Kidney Disease
Interventions
Moda-flx Hemodialysis System
Device
Lead sponsor
Diality Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Ontario, California
Source: ClinicalTrials.gov public record
Updated Jun 22, 2025 · Synced Oct 24, 2026, 9:59 AM EDT
Completed Not applicable Interventional

The Effect of Intradialytic Exercise on the Physical Function of People Undergoing Hemodialysis

NCT03944824
View directory record Official record
Conditions
End Stage Renal Failure on Dialysis, Frail Elderly Syndrome
Interventions
Exercise Plan using resistance bands, Modified Fried Frailty Scale
Other · Diagnostic Test
Lead sponsor
Satellite Healthcare
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Milpitas, California
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Oct 24, 2026, 9:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Mediating Effects of Decentering on Self-Management of Stress and End of Life Planning

NCT02842047
View directory record Official record
Conditions
Stage IV Gastrointestinal Cancer, Advanced Gynecological Cancer
Interventions
Stop, Breathe & Think™, End of Life Planning Videos, Caregiver wellness videos
Behavioral
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 4, 2019 · Synced Oct 24, 2026, 9:59 AM EDT
Completed Phase 2 Interventional Results available

Ledipasvir/Sofosbuvir in Adults With Chronic Hepatitis C Virus (HCV) Infection Who Are on Dialysis for End Stage Renal Disease

NCT03036839
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
LDV/SOF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
6
States / cities
Boston, Massachusetts • Detroit, Michigan • The Bronx, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 24, 2026, 9:59 AM EDT
Completed Not applicable Interventional Results available

SPIRIT for Persons With Dementia and Complex Multimorbidity

NCT04108000
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
SPIRIT-Dementia, Usual Care
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
4
States / cities
Atlanta, Georgia • Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Oct 24, 2026, 9:59 AM EDT
Completed Phase 2 Interventional Results available

Helping Olfaction and Nutrition On Renal Replacement

NCT02479451
View directory record Official record
Conditions
End Stage Renal Disease, Olfactory Disorders
Interventions
Theophylline
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 9, 2024 · Synced Oct 24, 2026, 9:59 AM EDT
Completed Not applicable Interventional Results available

Study to Determine the Efficacy of Real-time CGM in Preventing Hypoglycemia Among Insulin-treated Patients With DM2 on Hemodialysis, Compared to Standard of Care (POC BG)

NCT04473430
View directory record Official record
Conditions
End-Stage Renal Disease, Type 2 Diabetes
Interventions
Dexcom Real-time G6 Continuous Glucose Monitoring System (CGM), POC Glucose Testing
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 24, 2026, 9:59 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Duke APOL1 Research Biorepository

NCT04160507
View directory record Official record
Conditions
End Stage Kidney Disease
Interventions
Biorepository
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 24, 2026, 9:59 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Utility of Exercise-induced N-terminal (NT) Pro-brain Natriuretic Peptide Levels in Predicting Prognosis in Asymptomatic Aortic Stenosis

NCT00567437
View directory record Official record
Conditions
Aortic Stenosis
Interventions
NT-pro-BNP levels
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 24, 2012 · Synced Oct 24, 2026, 9:59 AM EDT
Terminated Not applicable Interventional Results available

Outcomes for One-stage and Two-stage Brachial Basilic Arteriovenous Fistulas

NCT04376567
View directory record Official record
Conditions
End Stage Renal Failure, Hemodialysis Access Failure, Arterio-venous Fistula
Interventions
One stage approach
Procedure
Lead sponsor
Tze-Woei Tan
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 24, 2026, 9:59 AM EDT
Completed Not applicable Interventional

VIDAS® TBI Real Life Performance in Subjects With Mild Traumatic Brain Injury (mTBI)

NCT06449183
View directory record Official record
Conditions
Mild Traumatic Brain Injury
Interventions
VIDAS® TBI Test [GFAP and UCH-L1 assays]
Diagnostic Test
Lead sponsor
BioMérieux
Industry
Eligibility
18 Years and older
Enrollment
903 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
5
States / cities
Orlando, Florida • Detroit, Michigan • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 24, 2026, 9:59 AM EDT
Completed Phase 3 Interventional Results available

Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes

NCT02513303
View directory record Official record
Conditions
Complication of Renal Dialysis, End Stage Renal Disease, End Stage Kidney Disease, ESRD, Chronic Kidney Failure, Complication of Hemodialysis, Vascular Access Complication, Arteriovenous Fistula
Interventions
Sirolimus, AV Fistula Surgery, Sirolimus-eluting Collagen Implant (SeCI)
Drug · Procedure · Device
Lead sponsor
Vascular Therapies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
4
States / cities
Huntsville, Alabama • Phoenix, Arizona • Escondido, California + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 24, 2026, 9:59 AM EDT
Recruiting Not applicable Interventional

Incremental Hemodialysis: The TwoPlus Trial

NCT05828823
View directory record Official record
Conditions
End-Stage Kidney Disease
Interventions
Hemodialysis twice weekly, Hemodialysis thrice weekly
Device · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
10
States / cities
Jacksonville, Florida • Atlanta, Georgia • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 24, 2026, 9:59 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of PTC124 in Duchenne Muscular Dystrophy

NCT00264888
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
PTC124
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
5 Years and older · Male only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
3
States / cities
Cincinnati, Ohio • Philadelphia, Pennsylvania • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 14, 2009 · Synced Oct 24, 2026, 9:59 AM EDT
Completed Not applicable Interventional Results available

Ellipsys Vascular Access System Post Market Surveillance (PS) Study

NCT04484220
View directory record Official record
Conditions
Renal Disease, End Stage, Kidney Disease, End-Stage, AV Fistula, Fistulas Arteriovenous
Interventions
Ellipsys Vascular Access System
Device
Lead sponsor
Medtronic Endovascular
Industry
Eligibility
18 Years to 80 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
12
States / cities
Riverside, California • New Haven, Connecticut • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 24, 2026, 9:59 AM EDT
Completed Phase 3 Interventional Results available

A Long-Term Safety Extension Trial of Ferric Citrate in Patients With End-Stage Renal Disease (ESRD) on Dialysis

NCT01554982
View directory record Official record
Conditions
End Stage Renal Disease, Kidney Failure, Renal Failure, Hyperphosphatemia, ESRD
Interventions
ferric citrate
Drug
Lead sponsor
Keryx Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
33
States / cities
Los Angeles, California • Aurora, Colorado • Westminster, Colorado + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Oct 24, 2026, 9:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety of Experimental Medication BMS986165 in Participants With Normal Kidney Function and Participants With Mild to End-Stage Kidney Disease.

NCT03890770
View directory record Official record
Conditions
Renal Impairment, Healthy Volunteer
Interventions
BMS-986165
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 12, 2021 · Synced Oct 24, 2026, 9:59 AM EDT
Completed Phase 3 Interventional Results available

Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment

NCT00614939
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Saxagliptin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
11
States / cities
Concord, California • Sacramento, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated May 19, 2011 · Synced Oct 24, 2026, 9:59 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of AB023 (Xisomab 3G3) in End Stage Renal Disease Patients on Chronic Hemodialysis

NCT03612856
View directory record Official record
Conditions
End Stage Renal Disease, Thrombosis
Interventions
AB023- Dose 1, AB023-Dose 2, placebo
Drug
Lead sponsor
Aronora, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced Oct 24, 2026, 9:59 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy Study of the Effect of Etanercept in Hemodialysis Patients

NCT00293202
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Etanercept, Placebo
Drug
Lead sponsor
Kaysen, George A., M.D., Ph.D.
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Oct 24, 2026, 9:59 AM EDT